Pulse Biosciences Inc (NASDAQ:PLSE) shares saw strong trading volume on Friday . 1,589,182 shares were traded during mid-day trading, an increase of 991% from the previous session’s volume of 145,607 shares.The stock last traded at $20.10 and had previously closed at $18.18.
Several research analysts recently issued reports on the stock. BidaskClub raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. ValuEngine raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st.
Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Friday, March 16th. The company reported ($0.53) earnings per share (EPS) for the quarter.
A number of large investors have recently bought and sold shares of PLSE. Bank of New York Mellon Corp increased its holdings in shares of Pulse Biosciences by 113.9% during the third quarter. Bank of New York Mellon Corp now owns 55,567 shares of the company’s stock worth $1,034,000 after buying an additional 29,588 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Pulse Biosciences by 13.8% during the third quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock worth $1,143,000 after buying an additional 7,465 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Pulse Biosciences by 1,785.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 7,295 shares of the company’s stock worth $172,000 after buying an additional 6,908 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth approximately $7,975,000. Finally, Brown Advisory Inc. acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth approximately $248,000. 10.84% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at www.tickerreport.com/banking-finance/3355119/pulse-biosciences-plse-sees-strong-trading-volume.html.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.